Sirolimus-induced inflammatory papules with acquired reactive perforating collagenosis

Dermatology

Volumn 216, Issue 3, 2008, Pages 239-242

  Lubbe J ^a,b   Sorg, O ^a   Male P J ^a   Saurat, J H ^a   Masouye I ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b HUG   (Switzerland)

Author keywords

Dermatosis, perforating; Follicular papules; Sirolimus

Indexed keywords

CYCLOSPORIN; FLUVOXAMINE; HYDROXYCHLOROQUINE; OXAZEPAM; PANTOPRAZOLE; PEGINTERFERON ALPHA; RAPAMYCIN; RIBAVIRIN;

ADULT; ARTICLE; CASE REPORT; COMBINATION CHEMOTHERAPY; DRUG INDUCED SEBORRHEIC DERMATITIS; DRUG WITHDRAWAL; ECZEMA; FEMALE; FOLLOW UP; GRAFT INFECTION; HEPATITIS C; HISTOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; LEG EDEMA; LIVER TRANSPLANTATION; LYMPHOCYTIC INFILTRATION; PAPULE; PRIORITY JOURNAL; SEBORRHEIC DERMATITIS; SEBUM; SKIN BIOPSY; SKIN NODULE;

ACNEIFORM ERUPTIONS; ANTI-INFLAMMATORY AGENTS; COLLAGEN; COLLAGEN DISEASES; DRUG ERUPTIONS; FEMALE; HUMANS; HYDROXYCHLOROQUINE; IMMUNOSUPPRESSIVE AGENTS; LIVER TRANSPLANTATION; MIDDLE AGED; SEBACEOUS GLANDS; SEBUM; SIROLIMUS; SKIN;

EID: 40949083553     PISSN: 10188665     EISSN: None     Source Type: Journal    
DOI: 10.1159/000112934     Document Type: Article

References (28)

1. Euvrard S, Ulrich C, Lefrancois N: Immunosuppressants and skin cancer in transplant patients: focus on rapamycin. Dermatol Surg 2004;30:628-633.
2. Saunders RN, Metcalfe MS, Nicholson ML: Rapamycin in transplantation: a review of the evidence. Kidney Int 2001;59:3-16.
3. Stucki L, Piguet V: The paradox of sirolimus-induced immunosuppression and tumor control. Dermatology 2006;213:3-5.
4. Stallone G, Schena A, Infante B, Di Paolo S, Loverre A, Maggio G, Ranieri E, Gesualdo L, Schena FP, Grandaliano G: Sirolimus for Kaposi's sarcoma in renal-transplant recipients. N Engl J Med 2005;352:1317-1323.
5. Gonzalez-Lopez MA, Rodrigo E, Gonzalez-Vela MC, Fernandez-Llaca H, Arias-Rodriguez MA, Val-Bernal JF: Posttransplant Kaposi's sarcoma restricted to the site of a previous deep venous thrombosis: abrupt onset after withdrawal of sirolimus. Dermatology 2006;213:30-33.
6. Mahe E, Morelon E, Lechaton S, Sang KH, Mansouri R, Ducasse MF, Mamzer-Bruneel MF, de Prost Y, Kreis H, Bodemer C: Cutaneous adverse events in renal transplant recipients receiving sirolimus-based therapy. Transplantation 2005;79:476-482.
7. Mahe E, Morelon E, Lechaton S, Kreis H, de Prost Y, Bodemer C: Angioedema in renal transplant recipients on sirolimus. Dermatology 2007;214:205-209.
8. Schaffellner S, Jakoby E, Kniepeiss D, Stadlbauer V, Duller D, Iberer F, Tscheliessnigg KH: Center experience in liver transplantation (LTX): management of dermal side effects caused by sirolimus. Int Immunopharmacol 2005;5:137-140.
9. Montalbano M, Neff GW, Yamashiki N, Meyer D, Bettiol M, Slapak-Green G, Ruiz P, Manten E, Safdar K, O'Brien C, Tzakis AG: A retrospective review of liver transplant patients treated with sirolimus from a single center: an analysis of sirolimus-related complications. Transplantation 2004;78:264-268.
10. Kahan BD: Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study. The Rapamune US Study Group. Lancet 2000;356:194-202.
11. Vasquez EM: Sirolimus: a new agent for prevention of renal allograft rejection. Am J Health Syst Pharm 2000;57:437-448; quiz 449-451.
12. Mahe E, Morelon E, Lechaton S, Drappier J, De Prost Y, Kreis H, Bodemer C: Acne in recipients of renal transplantation treated with sirolimus: clinical, microbiologic, histologic, therapeutic, and pathogenic aspects. J Am Acad Dermatol 2006;55:139-142.
13. Kunzle N, Venetz JP, Pascual M, Panizzon RG, Laffitte E: Sirolimus-induced acneiform eruption. Dermatology 2005;211:366-369.
14. Antille C, Saurat J-H, Lübbe J: Induction d'éruptions acnéiformes par le sirolimus/ everolimus: présentation de 4 cas. Dermatol Helv 2005;6:53.
15. Sperling L, Tomaszewski M, Thomas D: Viral-associated trichodysplasia in patients who are immunocompromised. J Am Acad Dermatol 2004;50:318-322.
16. Heaphy MR Jr, Shamma HN, Hickmann M, White MJ: Cyclosporine-induced folliculodystrophy. J Am Acad Dermatol 2004;50:310-315.
17. Daneshpazhooh M, Asgari M: Follicular dystrophy of immunosuppression. J Am Acad Dermatol 2005;52:540.
18. Saray Y, Seckin D, Bilezikci B: Acquired perforating dermatosis: clinicopathological features in twenty-two cases. J Eur Acad Dermatol Venereol 2006;20:679-688.
19. Patterson JW: The perforating disorders. J Am Acad Dermatol 1984;10:561-581.
20. Yanagihara M, Fujita T, Shirasaki A, Ishiguro K, Kawahara K, Ueda K: The pathogenesis of the transepithelial elimination of the collagen bundles in acquired reactive perforating collagenosis. A light and electron microscopical study. J Cutan Pathol 1996;23:398-403.
21. Kawakami T, Soma Y, Mizoguchi M, Saito R: Immunohistochemical analysis of transforming growth factor-beta3 expression in acquired reactive perforating collagenosis. Br J Dermatol 2001;144:197-199.
22. Tracey C, Hawley C, Griffin AD, Strutton G, Lynch S: Generalized, pruritic, ulcerating maculopapular rash necessitating cessation of sirolimus in a liver transplantation patient. Liver Transpl 2005;11:987-989.
23. Kahn D, Spearman CW, Mall A, Shepherd E, Engelbrecht G, Lotz Z, Tyler M: The effect of rapamycin on the healing of the ureteric anastomosis and wound healing. Transplant Proc 2005;37:830-831.
24. Kahn D, Spearman CW, Mall A, Shepherd E, Engelbrecht G, Lotz Z, Tyler M: Effect of rapamycin on the healing of the bile duct. Transplant Proc 2005;37:832-833.
25. Javier AF, Bata-Csorgo Z, Ellis CN, Kang S, Voorhees JJ, Cooper KD: Rapamycin (sirolimus) inhibits proliferating cell nuclear antigen expression and blocks cell cycle in the G1 phase in human keratinocyte stem cells. J Clin Invest 1997;99:2094-2099.
26. Agero AL, Dusza SW, Benvenuto-Andrade C, Busam KJ, Myskowski P, Halpern AC: Dermatologic side effects associated with the epidermal growth factor receptor inhibitors. J Am Acad Dermatol 2006;55:657-670.
27. Nanney LB, Magid M, Stoscheck CM, King LE Jr: Comparison of epidermal growth factor binding and receptor distribution in normal human epidermis and epidermal appendages. J Invest Dermatol 1984;83:385-393.
28. Laffitte E, Saurat JH: Kinase inhibitor-induced pustules. Dermatology 2005;211:305-306.